Which has stronger earnings & valuation, AGMB or LKFT?

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Lakefront Biotherapeutics American Depositary Shares $990.57M 2.04 $363.05M -$1.41 N/A

Is AGMB or LKFT more profitable?

Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Which has higher earnings and valuation, DMRA or AGMB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Is DMRA or AGMB more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% AgomAb Therapeutics N/A N/A N/A

Which has preferable valuation and earnings, AGMB or IMCR?

Immunocore has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Immunocore $430.78M 3.77 -$35.51M -$0.37 N/A

Does the media refer more to AGMB or IMCR?

In the previous week, AgomAb Therapeutics and AgomAb Therapeutics both had 2 articles in the media. Immunocore's average media sentiment score of 0.59 beat AgomAb Therapeutics' score of 0.00 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunocore 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, NTLA or AGMB?

AgomAb Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Intellia Therapeutics $67.67M 25.53 -$412.69M -$3.36 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Does the media refer more to NTLA or AGMB?

In the previous week, Intellia Therapeutics had 3 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 5 mentions for Intellia Therapeutics and 2 mentions for AgomAb Therapeutics. Intellia Therapeutics' average media sentiment score of 0.29 beat AgomAb Therapeutics' score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, AGMB or FBRX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Forte Biosciences N/A N/A -$69.38M -$4.65 N/A

Is AGMB or FBRX more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Forte Biosciences N/A -94.82% -77.68%

AgomAb Therapeutics (AGMB) Competitors

$10.77 -0.72 (-6.27%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$10.76 -0.01 (-0.06%)

As of 04:11 AM Eastern

Compare

AGMB vs. LKFT, DMRA, IMCR, NTLA, and FBRX

Should you buy AgomAb Therapeutics stock or one of its competitors? AgomAb Therapeutics's main competitors and comparable companies include Lakefront Biotherapeutics American Depositary Shares (LKFT), Damora Therapeutics, Inc. Common Stock (DMRA), Immunocore (IMCR), Intellia Therapeutics (NTLA), and Forte Biosciences (FBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AgomAb Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

AgomAb Therapeutics (NASDAQ:AGMB) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Lakefront Biotherapeutics American Depositary Shares	$990.57M	2.04	$363.05M	-$1.41	N/A

AgomAb Therapeutics presently has a consensus target price of $37.50, indicating a potential upside of 248.19%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $37.00, indicating a potential upside of 20.44%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe AgomAb Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 5 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 7 mentions for Lakefront Biotherapeutics American Depositary Shares and 2 mentions for AgomAb Therapeutics. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.88 beat AgomAb Therapeutics' score of 0.00 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lakefront Biotherapeutics American Depositary Shares beats AgomAb Therapeutics on 7 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $44.00, indicating a potential upside of 115.26%. AgomAb Therapeutics has a consensus target price of $37.50, indicating a potential upside of 248.19%. Given AgomAb Therapeutics' higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

AgomAb Therapeutics' return on equity of 0.00% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
AgomAb Therapeutics	N/A	N/A	N/A

In the previous week, Damora Therapeutics, Inc. Common Stock had 1 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 3 mentions for Damora Therapeutics, Inc. Common Stock and 2 mentions for AgomAb Therapeutics. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.71 beat AgomAb Therapeutics' score of 0.00 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Damora Therapeutics, Inc. Common Stock beats AgomAb Therapeutics on 6 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Immunocore?

AgomAb Therapeutics (NASDAQ:AGMB) and Immunocore (NASDAQ:IMCR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

AgomAb Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. AgomAb Therapeutics' return on equity of 0.00% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Immunocore	-4.20%	-4.54%	-1.66%

AgomAb Therapeutics presently has a consensus target price of $37.50, suggesting a potential upside of 248.19%. Immunocore has a consensus target price of $56.38, suggesting a potential upside of 78.74%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe AgomAb Therapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

84.5% of Immunocore shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, AgomAb Therapeutics and AgomAb Therapeutics both had 2 articles in the media. Immunocore's average media sentiment score of 0.59 beat AgomAb Therapeutics' score of 0.00 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunocore	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunocore has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Immunocore	$430.78M	3.77	-$35.51M	-$0.37	N/A

Summary

AgomAb Therapeutics and Immunocore tied by winning 6 of the 12 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

In the previous week, Intellia Therapeutics had 3 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 5 mentions for Intellia Therapeutics and 2 mentions for AgomAb Therapeutics. Intellia Therapeutics' average media sentiment score of 0.29 beat AgomAb Therapeutics' score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AgomAb Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. AgomAb Therapeutics' return on equity of 0.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
AgomAb Therapeutics	N/A	N/A	N/A

AgomAb Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	25.53	-$412.69M	-$3.36	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

Intellia Therapeutics currently has a consensus price target of $20.98, suggesting a potential upside of 70.14%. AgomAb Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 248.19%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe AgomAb Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

88.8% of Intellia Therapeutics shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Intellia Therapeutics beats AgomAb Therapeutics on 7 of the 13 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Forte Biosciences?

AgomAb Therapeutics (NASDAQ:AGMB) and Forte Biosciences (NASDAQ:FBRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

In the previous week, AgomAb Therapeutics had 2 more articles in the media than Forte Biosciences. MarketBeat recorded 2 mentions for AgomAb Therapeutics and 0 mentions for Forte Biosciences. AgomAb Therapeutics' average media sentiment score of 0.00 equaled Forte Biosciences'average media sentiment score.

Company	Overall Sentiment
AgomAb Therapeutics	Neutral
Forte Biosciences	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A

AgomAb Therapeutics' return on equity of 0.00% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Forte Biosciences	N/A	-94.82%	-77.68%

AgomAb Therapeutics presently has a consensus target price of $37.50, suggesting a potential upside of 248.19%. Forte Biosciences has a consensus target price of $71.67, suggesting a potential downside of 6.91%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe AgomAb Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.6% of Forte Biosciences shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

AgomAb Therapeutics beats Forte Biosciences on 6 of the 9 factors compared between the two stocks.

Get AgomAb Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGMB vs. The Competition

Export

Metric	AgomAb Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$416.36M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	N/A	13.88	274.08	25.69
Price / Sales	N/A	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	N/A	15.40	10.47	6.32
Net Income	-$70.77M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-10.84%	-1.70%	-0.67%	0.17%
1 Month Performance	-15.99%	-6.17%	-3.17%	-3.27%
1 Year Performance	N/A	30.67%	15.14%	5.58%

AgomAb Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGMB AgomAb Therapeutics	3.4661 of 5 stars	$10.77 -6.3%	$37.50 +248.2%	N/A	$416.36M	N/A	N/A	62
LKFT Lakefront Biotherapeutics American Depositary Shares	2.1832 of 5 stars	$27.92 +4.5%	$30.67 +9.8%	-8.4%	$1.76B	$1.26B	N/A	1,310	News Coverage Analyst Upgrade Gap Up High Trading Volume
DMRA Damora Therapeutics, Inc. Common Stock	3.0014 of 5 stars	$24.75 -12.8%	$44.00 +77.8%	+384.4%	$1.75B	N/A	N/A	40	High Trading Volume
IMCR Immunocore	3.451 of 5 stars	$31.77 -2.1%	$56.38 +77.4%	-8.4%	$1.67B	$400.02M	N/A	524
NTLA Intellia Therapeutics	2.8933 of 5 stars	$11.36 -4.3%	$20.98 +84.7%	-27.8%	$1.66B	$67.67M	N/A	377

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGMB) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. LKFT, DMRA, IMCR, NTLA, and FBRX

How does AgomAb Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does AgomAb Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does AgomAb Therapeutics compare to Immunocore?

Summary

How does AgomAb Therapeutics compare to Intellia Therapeutics?

Summary

How does AgomAb Therapeutics compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. LKFT, DMRA, IMCR, NTLA, and FBRX

How does AgomAb Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Do institutionals and insiders have more ownership in AGMB or LKFT?

Which has stronger earnings & valuation, AGMB or LKFT?

Do analysts recommend AGMB or LKFT?

Is AGMB or LKFT more profitable?

Does the media prefer AGMB or LKFT?

Summary

How does AgomAb Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Which has higher earnings and valuation, DMRA or AGMB?

Do analysts recommend DMRA or AGMB?

Is DMRA or AGMB more profitable?

Does the media refer more to DMRA or AGMB?

Do insiders & institutionals have more ownership in DMRA or AGMB?

Summary

How does AgomAb Therapeutics compare to Immunocore?

Is AGMB or IMCR more profitable?

Do analysts rate AGMB or IMCR?

Do institutionals & insiders hold more shares of AGMB or IMCR?

Does the media refer more to AGMB or IMCR?

Which has preferable valuation and earnings, AGMB or IMCR?

Summary

How does AgomAb Therapeutics compare to Intellia Therapeutics?

Does the media refer more to NTLA or AGMB?

Is NTLA or AGMB more profitable?

Which has preferable earnings & valuation, NTLA or AGMB?

Do analysts rate NTLA or AGMB?

Do institutionals & insiders hold more shares of NTLA or AGMB?

Summary

How does AgomAb Therapeutics compare to Forte Biosciences?

Does the media prefer AGMB or FBRX?

Which has higher earnings and valuation, AGMB or FBRX?

Is AGMB or FBRX more profitable?

Do analysts rate AGMB or FBRX?

Do insiders & institutionals hold more shares of AGMB or FBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools